DNA nanoparticles for ophthalmic drug delivery
Standard
DNA nanoparticles for ophthalmic drug delivery. / Willem de Vries, Jan; Schnichels, Sven; Hurst, José; Strudel, Lisa; Gruszka, Agnieszka; Kwak, Minseok; Bartz-Schmidt, Karl-U; Spitzer, Martin S; Herrmann, Andreas.
in: BIOMATERIALS, Jahrgang 157, 03.2018, S. 98-106.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - DNA nanoparticles for ophthalmic drug delivery
AU - Willem de Vries, Jan
AU - Schnichels, Sven
AU - Hurst, José
AU - Strudel, Lisa
AU - Gruszka, Agnieszka
AU - Kwak, Minseok
AU - Bartz-Schmidt, Karl-U
AU - Spitzer, Martin S
AU - Herrmann, Andreas
N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.
PY - 2018/3
Y1 - 2018/3
N2 - Nucleic acids represent very appealing building blocks for the construction of nano-scaled objects with great potential applications in the field of drug delivery where multifunctional nanoparticles (NPs) play a pivotal role. One opportunity for DNA nanotechnology lies in the treatment of ophthalmic diseases as the efficacy of eye drops is impaired by the short survival time of the drug on the eye surface. As a consequence, topical administration of ocular therapeutics requires high drug doses and frequent administration, still rarely providing high bioavailability. To overcome these shortcomings we introduce a novel and general carrier system that is based on DNA nanotechnology. Non-toxic, lipid-modified DNA strands (12mers with 4 lipid modified thymines at the 5' end) form uniform NPs (micelles), which adhere to the corneal surface for extended periods of time. In a single self-assembly step they can be equipped with different drugs by hybridization with an aptamer. The long survival times of DNA NPs can be translated into improved efficacy. Their functionality was demonstrated in several ex-vivo experiments and in an in-vivo animal model. Finally, the NPs were confirmed to be applicable even for human tissue.
AB - Nucleic acids represent very appealing building blocks for the construction of nano-scaled objects with great potential applications in the field of drug delivery where multifunctional nanoparticles (NPs) play a pivotal role. One opportunity for DNA nanotechnology lies in the treatment of ophthalmic diseases as the efficacy of eye drops is impaired by the short survival time of the drug on the eye surface. As a consequence, topical administration of ocular therapeutics requires high drug doses and frequent administration, still rarely providing high bioavailability. To overcome these shortcomings we introduce a novel and general carrier system that is based on DNA nanotechnology. Non-toxic, lipid-modified DNA strands (12mers with 4 lipid modified thymines at the 5' end) form uniform NPs (micelles), which adhere to the corneal surface for extended periods of time. In a single self-assembly step they can be equipped with different drugs by hybridization with an aptamer. The long survival times of DNA NPs can be translated into improved efficacy. Their functionality was demonstrated in several ex-vivo experiments and in an in-vivo animal model. Finally, the NPs were confirmed to be applicable even for human tissue.
KW - Administration, Ophthalmic
KW - Animals
KW - Cornea
KW - DNA
KW - Drug Delivery Systems
KW - Eye Diseases
KW - Female
KW - Humans
KW - Mice
KW - Mice, Inbred C57BL
KW - Micelles
KW - Nanoparticles
KW - Ophthalmic Solutions
KW - Swine
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1016/j.biomaterials.2017.11.046
DO - 10.1016/j.biomaterials.2017.11.046
M3 - SCORING: Journal article
C2 - 29258013
VL - 157
SP - 98
EP - 106
JO - BIOMATERIALS
JF - BIOMATERIALS
SN - 0142-9612
ER -
